Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 vs Lucentis in Diabetic Macular Edema
NCT07515079Phase 3Recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BAT5906 in diabetic macular edema (DME) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Best-Corrected Visual Acuity at 52 weeks. Started Oct 2024; status: recruiting.
02
Drugs
BAT5906
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07515079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515079.